ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 639 • 2013 ACR/ARHP Annual Meeting

    Examination Of The Cytokine Profile Of The Cerebrospinal Fluid In Neuropsychiatric Systemic Lupus Erythematosus

    Kunihiro Ichinose1, Takeshi Ushigusa2, Yoshikazu Nakashima3, Takahisa Suzuki3, Yoshiro Horai4, Shin-ya Kawashiri2, Naoki Iwamoto2, Mami Tamai3, Kazuhiko Arima4, Hideki Nakamura2, Tomoki Origuchi5 and Atsushi Kawakami4, 1Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Examination of the cytokine profile of the cerebrospinal fluid in neuropsychiatric systemic lupus erythematosusBackground/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in systemic…
  • Abstract Number: 640 • 2013 ACR/ARHP Annual Meeting

    Systemic Lupus Erythematosus Patients With Atherosclerosis Are Characterised By a Distinct Invariant Natural Killer T Cell Phenotype and Altered CD1d-Mediated Lipid Antigen Presentation

    Edward Smith1, Sara Croca2, Andrew Pitcher1, D.A. Isenberg1, Anisur Rahman3 and Elizabeth C. Jury4, 1Centre for Rheumatology Research, University College London, London, United Kingdom, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 3Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, 4Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom

    Background/Purpose: It is widely reported that systemic lupus erythematosus (SLE) patients have an increased risk of atherosclerosis compared to the general population, irrespective of traditional…
  • Abstract Number: 641 • 2013 ACR/ARHP Annual Meeting

    Vitamin D Increases The Number and Function Of Myeloid Angiogenic Cells In Systemic Lupus Erythematosus

    John A. Reynolds1, David W. Ray2, Terence O'Neill3, M. Yvonne Alexander4 and Ian N. Bruce5, 1Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, 2Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, 4Healthcare Science Research Institute, Faculty of Science and Engineering, Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, 5Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have an increased prevalence of cardiovascular disease (CVD).  Vitamin D deficiency is common in SLE and an independent…
  • Abstract Number: 614 • 2013 ACR/ARHP Annual Meeting

    Causes Of Mortality In Lupus Patients Followed Prospectively At a Large Single-Centre Lupus Clinic

    Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Survival rates of patients with systemic lupus erythematosus (SLE) have improved significantly over the last four decades. Mortality rates remain high, however, and are…
  • Abstract Number: 602 • 2013 ACR/ARHP Annual Meeting

    Repeat Biopsy In Lupus Nephritis: A Single-Center Experience

    Josefina Marin1, Marina Scolnik2, Eliana Lancioni3, Gustavo Greloni4, Cristian Quiroz5, Johana Zacariaz3, Carla Saucedo6, Luis J. Catoggio2 and Enrique R. Soriano2, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 3Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 6Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Renal involvement in systemic lupus erythematosus (SLE) is an important cause of morbidity and even mortality. Lupus nephritis has diverse morphologic manifestations with varying clinical…
  • Abstract Number: 603 • 2013 ACR/ARHP Annual Meeting

    Factors Associated With a Double Increase In Serum Creatinine In Biopsy Proven Lupus Nephritis From a Single Center In Spain

    Raúl Menor Almagro1, M. H. Cardiel2, Javier Rubio Garrido3, J. Luis de la Iglesia1, José Javier Perez Venegas1, María Mar Ruiz Tudela1, José Javier Salaberri1 and Manuel Paez-Camino1, 1Rheumatology, Hospital de Jerez, Jerez de la Frontera, Spain, 2Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 3Pathology, Hospital de Jerez, Jerez de la Frontera, Spain

    Background/Purpose: Lupus nephritis is a common and feared complication in systemic lupus erythematosus (SLE). Clinicians have relied on different variables to help to predict those…
  • Abstract Number: 604 • 2013 ACR/ARHP Annual Meeting

    Mycophenolate Mofetil Is Not Associated With Reduced Cardiovascular Or Lupus Damage Accumulation In a Cross-Sectional Lupus Cohort Study

    Maureen A. McMahon1, Maria Dall'era2, Eliza Chakravarty3, Joseph E. Craft4, Gary S. Gilkeson5, Kenneth C. Kalunian6, R. John Looney7, Gerald McGwin Jr.8 and Meggan Mackay9, 1Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Yale University School of Medicine, Internal Medicine, Section of Rheumatology, New Haven, CT, 5Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 6UCSD School of Medicine, La Jolla, CA, 7Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 8Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 9Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose: Mycophenolate mofetil (MMF) is frequently used for the treatment of lupus.  The immune-modulating effects of MMF extend beyond effects on lymphocyte proliferation, and include…
  • Abstract Number: 605 • 2013 ACR/ARHP Annual Meeting

    Childhood Lupus Nephritis: Long Term Outcome Of 91biopsy Proven Cases From India

    Puja Srivastava1, Bonnie Abujam2, Ramnath Misra1, Able Lawrence1, Vikas Agarwal1 and Amita Aggarwal1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Postgraduate Institute of Medical Education and Research, Chandigarh, India

    Background/Purpose: Childhood SLE has a higher prevalence of lupus nephritis (LN) as well as proliferative LN than adults. There is ethnic variation in response to…
  • Abstract Number: 606 • 2013 ACR/ARHP Annual Meeting

    Characteristics Of Lupus Nephritis:  Data From a Large Multicenter Registry Of Patients With Systemic Lupus Erythematosus

    Diane L. Kamen1, Graciela S. Alarcon2, Jill P. Buyon3, Mary Anne Dooley4, Richard A. Furie5, David S. Pisetsky6 and Tammy O. Utset7, 1Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 2Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 6Department of Medicine, Duke University Medical Center, Durham, NC, 7Rheumatology, University of Chicago Medical Center, Chicago, IL

    Background/Purpose: Renal disease is strongly associated with morbidity and mortality among SLE patients. We utilized the Lupus Clinical Trials Consortium, Inc. longitudinal registry of SLE…
  • Abstract Number: 607 • 2013 ACR/ARHP Annual Meeting

    Venous Thromboembolic Disease Is Associated With Increased Length Of Stay and In-Hospital Mortality In Hospitalized SLE Patients: A Multi-State, Population-Based Study

    Matthew Cascino1, Laura Trupin1, Sara Murray1, Mary Margaretten2, Edward H. Yelin3 and Jinoos Yazdany1, 1Medicine, University of California, San Francisco, San Francisco, CA, 2Rheumatology, University of California, San Francisco, San Francisco, CA, 3Arthritis Research Group, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are at increased risk for venous thromboembolism (VTE). However, there is limited population-based data on outcomes associated with…
  • Abstract Number: 608 • 2013 ACR/ARHP Annual Meeting

    Effect Of Renal Damage On Extra-Renal Organ Damage and Mortality In Patients With Systemic Lupus Erythematosus (SLE): A Longitudinal Cohort Study Of 756 Patients

    Chi Chiu Mok1, Ling Yin Ho1, Kar Li Chan1 and Chi Hung To2, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Tuen Mun Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the effect of renal damage on extra-renal organ damage and mortality in patients with SLE. Methods: Patients who fulfilled >=4 ACR criteria…
  • Abstract Number: 609 • 2013 ACR/ARHP Annual Meeting

    Increased Arterial Stiffness In Systemic Lupus Erythematosus (SLE) Patients At Low Risk For Cardiovascular Disease: A Cross-Sectional Controlled Study

    Karim Sacre1, Brigitte Escoubet2, Maria Chauchard3, Antoine Dossier3, Marie-Paule Chauveheid4 and Thomas Papo5, 1Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 2Cardiology, University Paris-7, INSERM U872, APHP, Bichat Hospital, Paris, France, 3Internal Medicine, University Paris-7, APHP, Bichat Hospital, Paris, France, 4Internal Medicine,, University Paris-7, APHP, Bichat Hospital, Paris, France, 5Internal Medicine, Bichat Hospital, Paris, Paris, France

    Background/Purpose: Accelerated atherosclerosis accounts for significant premature mortality rates among systemic lupus erythematosus (SLE) patients. Arterial stiffness reflects changes in mechanical properties of vascular wall…
  • Abstract Number: 610 • 2013 ACR/ARHP Annual Meeting

    Disease Specific Quality Of Life Domains Are Impaired In Patients With Lupus Nephritis?

    Meenakshi Jolly1, Zineb Aouhab2, Sergio Toloza3, Ana M. Bertoli4, Ivana Blazevik5, Luis M. Vila6, Ioana Moldovan7, Karina Marianne D. Torralba8, Arif Kaya9, Berna Goker10, Mehmet E. Tezcan11, Seminur Haznedaroglu12, Josiane Bourré-Tessier13, Ann E. Clarke14, D.J. Wallace15, Michael H. Weisman16 and Graciela S. Alarcon17, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Medicine, John H Stroger Hospital, Chicago, IL, 3Hospital San Juan Bautista, Catamarca, Argentina, 4Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, 5University of Buenos Aires, Buenos Aries, Argentina, 6Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, 7Loma Linda Univ Medical Center, Loma Linda, CA, 8Rheumatology/Int Med, USC Keck Schl of Medicine, Los Angeles, CA, 9Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, 10Internal Medicine-Rheumatology, Gazi University, Ankara, Turkey, 11Rheumatology, Dr. Lutfi Kirdar Kartal EA Hastanesi, Istanbul, Turkey, 12Internal Medicine-Rheumatology, Gazi University School of Medicine, Ankara, Turkey, 13Rheumatology, McGill University, Montréal, QC, Canada, 14Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, 15Cedars-Sinai Medical Center, Los Angeles, CA, 16Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 17Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Often systemic Lupus Erythematosus (SLE) patients with Lupus Nephritis (LN) require frequent visits with their health care providers, follow up, and exposure to immunosuppressive…
  • Abstract Number: 611 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Transjugular Renal Biopsy In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Retrospective Monocentric Study Of 91 Procedures

    Alexis Mathian1, Maud Cazenave2, Laurent Arnaud3, Nathalie Costedoat-Chalumeau4, Du Boutin-LE Thi Huong5, Ahlem Chaib5, Fleur Cohen-Aubart6, Julien Haroche3, Miguel Hié5, Makoto Miyara5, Philippe Rouvier7, Jean-Charles Piette8, Philippe Cluzel9 and Zahir Amoura10, 1Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Internal Medicine, Paris, France, 2Service de médecine interne 2, Centre de référence National pour le Lupus et le Syndrome des antiphospholipides, CHU Pitié-Salpêtrière, APHP, Paris, France, Paris, France, 3Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 4Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 5Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 6Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, 7Service d'anatomie pathologie, CHU Pitié-Salpêtrière, APHP, Paris, France, Paris, France, 8Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, 9Cadiovascular Imaging and Interventional Radiology, Pitié-Salpétrière, Paris, France, 10Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France

    Background/Purpose: Percutaneous renal biopsy requires a long duration discontinuation of antithrombotic treatment which can increase the risk of thrombosis in patient with Systemic Lupus Erythematosus…
  • Abstract Number: 612 • 2013 ACR/ARHP Annual Meeting

    Increased Expression Of Membrane Endothelial Protein C Receptor Associates With Poor Response In Lupus Nephritis Independent Of Chronicity Index 

    Barbara Mendez1, Ming Wu2, Dominick Santoriello2, Laura Barisoni3, Peter M. Izmirly1, Jill P. Buyon1 and Robert M. Clancy4, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Pathology, New York University School of Medicine, New York, NY, 3Pathology, University of Miami Hospital, Miami, FL, 4Medicine, New York University School of Medicine, New York, NY

    Background/Purpose:  While a consensus is that a high chronicity index (CI) is associated with a greater risk for progression to renal failure in lupus nephritis…
  • « Previous Page
  • 1
  • …
  • 2206
  • 2207
  • 2208
  • 2209
  • 2210
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology